Как цитировать
Аннотация
Ингибиторы контрольных точек иммунного ответа являются наиболее перспективной опцией лечения для многих гистологических подтипов злокачественных новообразований, обеспечивая длительный объективный ответ и увеличение общей выживаемости. В настоящее время появляется все больше данных о специфической гетерогенности клинических и радиологических ответов на фоне иммунотерапии, таких как псевдопрогрессирование и гипепрогрессирование. Учитывая данные феномены, перед клиницистом встает серьезный вопрос о необходимости выделения определенной когорты пациентов, для которых терапия иммуноонкологическими препаратами будет максимально эффективной и безопасной. Данный обзор демонстрирует результаты исследований, описывающие упомянутые феномены.Библиографические ссылки
Collin M. Immune checkpoint inhibitors: a patent review (2010-2015) // Expert Opin Ther Pat. 2016 May;26(5):555-64.
Hodi F.S., Wolchok J.D. et al., Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial // Lancet Oncol. 2018 Nov;19(11):1480-1492.
Kim H., Comey S., Hausler K., Cook G. A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma // J Pharm Policy Pract. 2018 Feb 13;11:4.
Kanda S., Goto K., Shiraishi H. et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study // Ann. Oncol. 27 (12) (2016) 2242-2250.
P. Sharma P., Allison J.P. The future of immune checkpoint therapy // Science 348 (6230) (2015) 56-61.
Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer // N. Engl. J. Med. 373 (17) (2015) 1627-1639.
Herbst R.S., Baas P., Kim D.W. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYN0TE-010): a randomised controlled trial // Lancet. 2016 Apr 9;387(10027):1540-1550.
Plimack E.R., Bellmunt J., Gupta S. et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a nonrandomised, open-label, phase 1b study // Lancet Oncol. 18 (2) (2017) 212-220.
Chang L., Chang M., Chang F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy // Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):15-21.
Schmidinger M. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma // Curr Opin Urol 2018;28(1):29-34.
Barata PC., Rini B. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 2017;67(6):507-24. DOI: 10.3322/caac.21411
Ross K., Jones R.J. Immune checkpoint inhibitors in renal cell carcinoma // Clin Sci (Lond) 2017; 131(21): 2627-42.
Motzer R.J. et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial // J Clin Oncol. 2015; 33:1430-1437.
Motzer R.J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma // N Engl J Med. 2015; 373:1803-1813.
Beckermann K.E., Johnson D.B., Sosman J.A. PD-1/PD-L1 blockade in renal cell cancer // Expert Rev Clin Immunol. 2017 Jan;13(1):77-84.
Eisenhauer E.A., Therasse P., Bogaerts J. et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) // Eur. J. Cancer. 45, Nr. 2, Januar 2009, S. 228-47.
Wolchok J.D., Hoos A., Bohnsack O. et.al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria // Clin Cancer Res 2009; 15(23).
Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements // Clin Cancer Res. 2013 Jul 15; 19(14):3936-43.
Nishino M., Gargano M., Suda M. et al. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? // J Immunother Cancer. 2014; 2: 17.
Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients //J Immunother Cancer. 2016; 4: 84.
Nishino M., Hatabu H., Hodi F.S. Imaging of cancer immunotherapy: current approaches and future directions // Radiology. 2019;290(1):9-22.
Katz S.I., Hammer M., Bagley S.J. et al. Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer // J Thorac Oncol. 2018;13(7):978-986.
Ferrara R., Mezquita L, Texier M. et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy // JAMA Oncol. 2018;4(11):1543-1552.
Nishino M., Giobbie-Hurder A., Manos M.P. et al. Immune related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions // Clin Cancer Res. 2017;23(16):4671-4679.
Wolchok J.D., Hamid O., Ribas A. Atypical patterns of response in patients (pts) with metastatic melanoma treated withpembrolizumab (MK-3475) in KEYNOTE-001 // J Clin Oncol. 2015;33(15 supplement):3000.
Tanizaki J., Hayashi H., Kimura M. et al. Report of two cases of pseudoprogression in patients with non-small cell Lung Cancer treated with nivolumab-including histological analysis of one case after tumor regression // Lung Cancer 102 (2016) 44-48.
Sasaki A., Nakamura Y, Mishima S. et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced Gastric Cancer // Gastric Cancer. 2019;22(4):793-802.
Kanjanapan Y, Day D., Wang L. et al. Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities // Cancer. 2019;125(8):1341-1349.
Brower V. Hyperprogressive disease with anti-PD-1 and anti-PD-L1 // Lancet. Oncol 2016;17(12):e527.
Champiat S., Dercle L., Ammari S., et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 // Clin. Cancer Res. 2017;23(8):1920-28.
Ferte C., Fernandez M., Hollebecque A. et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trial // Clin. Cancer Res. 2014;20(1):246-52.
Lo Russo G., Moro M., Sommariva M. et al. AntibodyFc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade // Clin. Cancer Res. 2018.
Champiat S., Dercle L., Ammari S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 // Clin. Cancer Res. 23 (8) (2017) 1920-1928.
Saada-Bouzid E., Defaucheux C., Karabajakian A. et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma // Ann. Oncol. 28 (7) (2017) 1605-1611.
Ito K., Schoder H., Teng R. et al. Prognostic value of baseline metabolic tumor volume measured on 18F-fluo-rodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy // Eur J Nucl Med Mol Imaging. 2019;46(4):930-939.
Lee C.K., Man J., Lord S. et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis // J. Thorac. Oncol. 12 (2) (2017) 403-407.
Tawbi H.A., Burgess M., Bolejack V. et al. Pembroli-zumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial // Lancet Oncol. 18 (11) (2017) 1493-1501.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2020